OGN: Organon Operating Profitability

Public company logo of Organon & Co (OGN)

Organon & Co. (OGN) maintains stable margins backed by patent protection for contraceptives and global distribution. The operating margin breakdown illustrates profitability trends, where 19.60 represents the current metric level. Business growth is driven by innovation licenses through biotech partnerships, although intense pressure from generic manufacturers necessitates significant promotional expenditures.

Organon & Co (OGN): Return on Sales by Operating Profit from 07/04/2022 to 11/19/2026

Financial and market metric breakdowns for Organon (OGN)

- price and consensus price forecast:
- market capitalization information:
Fundamental company valuation:Organon Pharma, OGN
Signature product of organon.com

Organon & Co. (OGN) maintains its own manufacturing plants in Europe and Asia to ensure supply stability, directly impacting cost management efficiency and the ultimate profitability of the core business. The recorded operating margin reflects the portion of operating profit in every dollar of revenue before interest and taxes, allowing investors to objectively assess the profitability of production assets and the quality of the company's operational management.